Briefing
BESPOKE CRC: postoperative ctDNA positivity tracked with shorter disease-free survival in stage II and III disease
In the final MRD analysis of the observational BESPOKE CRC study presented at ASCO GI 2025, ctDNA positivity in the postoperative window was associated with inferior disease-free survival in stage II disease (HR 10.4) and stage III disease (HR 10.1) among patients with a result in that window.